Among these drugs, pharmacological inhibitors of the receptor-interacting serine/threonine protein kinase 1 (RIPK1) have entered clinical trials for the treatment of autoimmune diseases (psoriasis, ulcerative colitis and rheumatoid arthritis), as well as some cancers and neurological disorders (Mifflin et al., 2020). Here, RIPK1 is linked to nervous system disorder.